MedTrace Logo

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

NCT03981003 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1150

Last updated 2024-05-14

No results posted yet for this study

Summary

The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.

In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood sample

2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Eric Thouvenot · CHU Nimes

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-22
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • France
  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03981003 on ClinicalTrials.gov